ImmunityBio, Inc.: all 115 studies
Page 1 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With SepsisNot yet recruitingNCT07783789Phase 2
- Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationNot yet recruitingNCT07628062Phase 2
- NAI for Sepsis With Persistent LymphopeniaNot yet recruitingNCT07578558Phase 2
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNot yet recruitingNCT07477366Phase 2
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingNCT07217496Phase 1
- Study of Relapsed/ Refractory B-cell Non- Hodgkin LymphomaRecruitingNCT07125872Phase 2
- A Study to Examine Anktiva for the Treatment of COVID-19.RecruitingNCT07123727Phase 2
- A Study to Assess Anktiva in Patients With Long Covid-19.RecruitingNCT07108036Phase 2
- Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation TherapyAvailableNCT06956547
- Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNot yet recruitingNCT06829823Phase 2
- ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder CancerAvailableNCT06810141
- ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCGRecruitingNCT06800963Phase 1/2
- Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InRecruitingNCT06745908Phase 3
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerRecruitingNCT06710288Phase 2
- Study for Subjects With Relapsed/Refractory Non- Hodgkin LymphomaRecruitingNCT05618925Phase 1
- A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIALTerminatedNCT06022224Phase 2/3Results posted
- THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 VaccinesTerminatedNCT05370040Phase 1/2Results posted
- A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior TherapiesTerminatedNCT04927884Phase 1/2Results posted
- COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USATerminatedNCT04732468Phase 1Results posted
- COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African AdultsCompletedNCT04710303Phase 1Results posted
- Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical VentilationTerminatedNCT04397796Phase 1Results posted
- Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19TerminatedNCT04385849Phase 1Results posted
- PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)TerminatedNCT04142359Results posted
- QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyTerminatedNCT03853317Phase 2Results posted
- QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedNCT03586869Phase 1/2Results posted
- QUILT 3.071: NANT Colorectal Cancer (CRC) VaccineTerminatedNCT03563157Phase 1/2Results posted
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedNCT03387111Phase 1/2Results posted
- QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03387098Phase 1/2Results posted
- QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedNCT03387085Phase 1/2Results posted
- QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803CompletedNCT03381586Phase 1Results posted
- QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03329248Phase 1/2Results posted
- QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyTerminatedNCT03136406Phase 1/2Results posted
- QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing CancerTerminatedNCT03127098Phase 1/2Results posted
- QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid TumorsCompletedNCT03027128Phase 1Results posted
- QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)TerminatedNCT02465957Phase 2Results posted
- QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabTerminatedNCT02384954Phase 1/2Results posted
- QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine ChordomaCompletedNCT02383498Phase 2Results posted
- Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue SarcomaCompletedNCT02235701Phase 1/2Results posted
- Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung CancerCompletedNCT02200757Phase 2Results posted
- QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT02099539Phase 1Results posted
- Phase 3 Study to Treat Patients With Soft Tissue SarcomasCompletedNCT02049905Phase 3Results posted
- A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's SarcomaCompletedNCT02029430Phase 2Results posted
- Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With GlioblastomaCompletedNCT02014844Phase 2Results posted
- A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid TumorsCompletedNCT01946789Phase 1Results posted
- QUILT-3.006 for Recurrent Medullary Thyroid CancerCompletedNCT01856920Phase 2Results posted
- QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT01670994Phase 1/2Results posted
- A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerTerminatedNCT01625260Phase 1/2Results posted
- Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic CancerCompletedNCT01580397Phase 2Results posted
- Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue SarcomaCompletedNCT01514188Phase 2Results posted
- Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress SyndromeCompletedNCT01438853Phase 1Results posted
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial CancerCompletedNCT01326871Phase 1/2Results posted
- QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the PancreasCompletedNCT01231347Phase 3Results posted
- QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEACompletedNCT01147965Phase 1/2Results posted
- QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic MelanomaTerminatedNCT01029873Phase 1/2Results posted
- QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid TumorsTerminatedNCT00819169Phase 1/2Results posted
- QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung CancerTerminatedNCT00807612Phase 1/2Results posted
- QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung CancerTerminatedNCT00791154Phase 1/2Results posted
- QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic CancerCompletedNCT00630552Phase 1/2Results posted
- QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast CancerCompletedNCT00626106Phase 2Results posted
- Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C InfectionCompletedNCT00606086Phase 2Results posted
- Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic MalignanciesCompletedNCT00496860Phase 1Results posted
- A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic LeukemiaTerminatedNCT07556757Phase 1
- ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder CancerWithdrawnNCT07551544Phase 3
- Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLCWithdrawnNCT07524257Phase 3
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)WithdrawnNCT07492888Phase 2
- Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired PneumoniaWithdrawnNCT07492875Phase 3
- Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic CancerWithdrawnNCT07488884Phase 1
- Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.WithdrawnNCT06765954Phase 2
- Immunotherapy Before and After SurgeryWithdrawnNCT06765902Phase 2
- Study for Participants With Relapsed/Refractory Non-Hodgkin LymphomaActive, not recruitingNCT06334991Phase 1
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaActive, not recruitingNCT06061809Phase 2
- Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By ApheresisCompletedNCT06040918Phase 1
- Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)Active, not recruitingNCT05981131
- IBRX-042 In Participants With HPV-Associated TumorsActive, not recruitingNCT05976828Phase 1
- HCW9218 for Advanced Pancreatic CancerCompletedNCT05304936Phase 1/2
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT04898543Phase 1
- COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based VaccinesWithdrawnNCT04845191Phase 1/2
- COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based VaccinesWithdrawnNCT04843722Phase 1/2
- COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy VolunteersCompletedNCT04591717Phase 1
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT04390399Phase 2
- QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell LymphomaWithdrawnNCT04052061Phase 1
- QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid CancersCompletedNCT04050709Phase 1
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnNCT03647423Phase 1/2
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnNCT03574649Phase 2
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnNCT03563170Phase 1/2
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnNCT03563144Phase 2
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnNCT03554109Phase 2
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03197571Phase 1/2
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnNCT03175666Phase 1/2
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnNCT03169738Phase 1/2
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03167177Phase 1/2
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnNCT03167164Phase 1/2
- QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerActive, not recruitingNCT03022825Phase 2/3
- QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-PaclitaxelCompletedNCT02559674Phase 1